Cardinal Health
CAH
$235.17
+1.70%
Cardinal Health, Inc. is a leading healthcare services company that sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies, hospitals, and healthcare providers, and also supplies medical-surgical products across North America, Europe, and Asia. As one of the three dominant pharmaceutical wholesalers in the U.S., alongside Cencora and McKesson, Cardinal Health holds a significant share of the market, with the trio controlling over 90% of the industry. The current investor narrative centers on the company's robust earnings performance and raised full-year profit outlook, which have driven strong stock appreciation, despite recent quarterly revenue falling short of Wall Street expectations, highlighting the tension between operational efficiency and top-line growth in a competitive distribution landscape.…
CAH
Cardinal Health
$235.17
Related headlines
Investment Opinion: Should I buy CAH Today?
Rating: Buy. Cardinal Health is a strong buy based on its robust growth trajectory, raised guidance, and attractive forward valuation. The analyst consensus is a Strong Buy with an average target price of $252.40, implying ~6.2% upside from the current price of $237.66. The company's dominant market position and low beta make it a defensive growth pick.
Sign up to view all
CAH 12-Month Price Forecast
The AI assessment is bullish on Cardinal Health, driven by its strong revenue growth, attractive forward valuation, and positive analyst sentiment. The company's dominant market position and low beta make it a defensive growth pick. However, the medium confidence reflects the risks of thin margins and potential revenue volatility. If the company can sustain its growth trajectory and expand margins, the stock has significant upside. Conversely, any signs of deceleration or margin compression would warrant a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cardinal Health's 12-month outlook, with a consensus price target around $270.60 and implied upside of +15.1% versus the current price.
Average Target
$270.60
0 analysts
Implied Upside
+15.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$235 - $292
Analyst target range
The target price range spans from a low of $215.00 to a high of $275.00, indicating a spread of $60, which reflects moderate uncertainty about the stock's future performance. The high target of $275 assumes continued strong execution, potential market share gains, and further margin expansion, while the low target of $215 suggests concerns about revenue growth sustainability or competitive pressures. The relatively tight spread (approximately 25% of the average target) suggests analysts have reasonably high conviction in the stock's direction, though the presence of a wide range highlights the inherent variability in healthcare distribution. Recent ratings have been stable, with no downgrades in the past six months, and the consensus has remained positive, supporting the strong buy stance.
Bulls vs Bears: CAH Investment Factors
Cardinal Health presents a compelling bull case driven by strong revenue growth, raised guidance, and an attractive forward valuation. The company's dominant market position and low beta provide stability, while analyst consensus remains strongly positive. However, the bear case highlights thin margins, a revenue miss, and a rich trailing valuation that could limit upside. Currently, the bull case has stronger evidence, supported by accelerating growth and a PEG ratio of 0.30, but the key tension is whether the company can sustain its earnings growth momentum to justify the premium valuation. If revenue growth decelerates or margins compress, the stock could face significant downside.
Bullish
- Strong Revenue Growth: Q3 FY2026 revenue grew 11.05% YoY to $60.94B, accelerating from prior quarters. This top-line momentum is driven by the Pharmaceutical segment, which contributed $56.11B, and supports the company's raised full-year outlook.
- Raised Full-Year Guidance: Management raised its full-year profit outlook, signaling confidence in continued operational efficiency. This positive revision, combined with a strong earnings beat in Q3, has driven the stock up 51.76% over the past year.
- Attractive Forward Valuation: The forward PE of 19.72x is well below the trailing PE of 25.93x, implying expected earnings growth of ~31%. With a PEG ratio of 0.30, the stock appears undervalued relative to its growth prospects.
- Strong Analyst Consensus: With 15 analysts, the consensus is a Strong Buy (mean rating 1.47). The average target price of $252.40 implies ~6.2% upside from the current price of $237.66, and the high target of $275 suggests potential for ~15.7% upside.
Bearish
- Revenue Miss in Q3: Despite strong earnings, Q3 revenue of $60.94B fell short of Wall Street expectations, causing the stock to drop sharply on April 30, 2026. This highlights potential top-line growth challenges in a competitive distribution landscape.
- Thin Profit Margins: Net margin is only 0.70% and operating margin is 1.02%, reflecting the low-margin nature of pharmaceutical distribution. Even small cost increases or pricing pressures could significantly impact profitability.
- High Valuation vs. History: The trailing PE of 25.93x is elevated compared to historical norms for a distributor. The stock trades near its 52-week high of $244.87, leaving limited room for multiple expansion and increasing downside risk if earnings disappoint.
- Negative ROE and Debt Concerns: ROE is -56.13% and debt-to-equity is -3.36, indicating negative shareholder equity, likely due to buybacks or accounting adjustments. This financial structure could limit flexibility and increase risk if interest rates rise.
CAH Technical Analysis
Cardinal Health's stock is in a strong uptrend, with a 1-year price change of +51.76%, significantly outperforming the S&P 500's +21.46% over the same period. The current price of $237.66 sits near the upper end of its 52-week range, at approximately 97% of the high of $244.87, indicating robust momentum and investor confidence. This positioning near the highs suggests the stock is being rewarded for its fundamental improvements, though it also raises the risk of short-term overextension.
Beta
0.52
0.52x market volatility
Max Drawdown
-20.6%
Largest decline past year
52-Week Range
$146-$258
Price range past year
Annual Return
+56.6%
Cumulative gain past year
| Period | CAH Return | S&P 500 |
|---|---|---|
| 1m | +4.5% | +2.9% |
| 3m | +20.5% | +5.0% |
| 6m | +6.5% | +13.9% |
| 1y | +56.6% | +20.4% |
| ytd | +14.3% | +13.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CAH Fundamental Analysis
Cardinal Health's revenue trajectory is solidly growing, with the most recent quarter (Q3 FY2026, ended March 31, 2026) reporting revenue of $60.94 billion, a YoY increase of 11.05% from $54.88 billion in the prior-year quarter. This growth is driven primarily by the Pharmaceutical segment, which generated $56.11 billion in revenue, while the GMPD segment contributed $3.15 billion and other operating segments added $1.71 billion. The multi-quarter trend shows consistent expansion, with revenue rising from $52.28 billion in Q1 FY2025 to $60.94 billion in Q3 FY2026, indicating accelerating growth that supports the investment case.
Quarterly Revenue
$60.9B
2026-03
Revenue YoY Growth
+11.1%
YoY Comparison
Gross Margin
4.1%
Latest Quarter
Free Cash Flow
$4.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CAH Overvalued?
Given that Cardinal Health has positive net income, the primary valuation metric selected is the price-to-earnings (PE) ratio. The trailing PE is 25.93x, while the forward PE is 19.72x, implying that the market expects earnings growth of approximately 31% over the next year. This gap between trailing and forward multiples suggests that investors are pricing in continued margin expansion and operational improvements, which are supported by the company's raised full-year guidance.
PE
32.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 13x~42x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cardinal Health operates with very thin margins, as evidenced by a net margin of 0.70% and operating margin of 1.02%. This leaves little room for error; a modest increase in costs or a pricing squeeze from customers could disproportionately impact earnings. The company's negative ROE (-56.13%) and negative debt-to-equity (-3.36) indicate a fragile equity base, potentially limiting financial flexibility. Additionally, the current ratio of 0.94 suggests potential liquidity concerns, as current liabilities exceed current assets. While free cash flow is positive at $4.39B TTM, the low margins and high leverage amplify operational risks.